Browsing Tag
Lantern Pharma
5 posts
Lantern Pharma highlights AI-powered cancer research platforms during UNT’s first AI for Biology & Medicine symposium
Find out how Lantern Pharma is redefining AI-driven cancer drug development with predictBBB.ai and LBx-AI at UNT’s inaugural AI4BM symposium.
Lantern Pharma announces collaboration with Oregon Therapeutics to advance AI-driven cancer drug development
Lantern Pharma Inc. (NASDAQ: LTRN) announced a strategic collaboration with French biotech company Oregon Therapeutics to enhance the…
Lantern Pharma gets FDA nod for LP-284 clinical trial in non-Hodgkin’s lymphoma
Lantern Pharma Inc. (NASDAQ: LTRN), a trailblazer in artificial intelligence (AI) and machine learning (ML) for targeted cancer…
Lantern Pharma gets FDA nod for Harmonic phase 2 clinical trial of LP-300
Lantern Pharma said that the US Food and Drug Administration (FDA) has authorized it to move ahead with…
Lantern Pharma bags FDA orphan drug status for LP-184 in pancreatic cancer
Lantern Pharma has secured orphan drug designation for its small molecule drug candidate LP-184 from the US Food…